Navigation Links
ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference

Clear Anti-Inflammatory Activity Demonstrated Among Patients with Active Disease

MOUNTAIN VIEW, Calif., May 23, 2007 /PRNewswire/ -- ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, presented data today from the company's Phase 2 clinical trial of Traficet-EN (CCX282-B), an orally-active anti-inflammatory agent that targets the chemokine receptor CCR9. Clinical results demonstrate that Traficet-EN is well tolerated and shows clinical activity in the treatment of patients with active Crohn's disease. These data (Abstract #1031) were presented in an oral session, "Advances in Crohn's Disease," at the Digestive Disease Week (DDW) 2007 Conference in Washington, D.C. by Satish Keshav, M.D., Ph.D., Gastroenterologist at the John Radcliffe Hospital, Oxford, and a clinical investigator for the study.

"Traficet-EN demonstrated promising evidence of efficacy in the treatment of Crohn's disease patients, particularly among patients with elevated CDAI and CRP measurements at baseline. These results, achieved after only four weeks of treatment, justify broader study of Traficet-EN," said Dr. Keshav. "Traficet-EN's potential to control Crohn's disease with a safe and effective oral capsule represents a paradigm shift in the treatment of this condition and a truly meaningful improvement in patient care."

Patients enrolled in the Phase 2 clinical trial were randomized to receive a once-daily 250 mg capsule of Traficet-EN or placebo for 28 days. Both Crohn's Disease Activity Index (CDAI) scores and C-reactive protein (CRP) levels were measured at baseline and on study days 8, 15 and 29. Among a defined subgroup of 39 patients identified as having more active disease, with CDAI scores of greater than or equal to 250 and CRP of greater than 7.5 mg/L at baseline, Traficet-EN demonstr ated clinical benefit. Fifty-eight percent of patients in the Traficet-EN group experienced a 70 point or greater drop in CDAI scores compared to 31 percent of those who received placebo. Importantly, Traficet-EN's anti-inflammatory activity was demonstrated by a decrease in CRP levels, which serve as a systemic marker of inflammation, of 11 mg/L in the treatment group compared to placebo.

"We are very pleased to have seen clear signs of clinical activity in this four week study of Traficet-EN. Patients with active disease reported significant improvement in their condition when treated with Traficet-EN compared to those in the control group," said Pirow Bekker, M.D., Ph.D., Vice President, Medical and Clinical Affairs of ChemoCentryx, Inc. "In addition, the results from this group of patients in our Phase 2 trial are in line with the latest research from key opinion leaders. Current research has shown that CDAI scores of 250 and above, combined with elevated CRP serum levels at baseline, help to identify patients with actual Crohn's disease and may thereby reduce the high placebo response rate frequently observed in Crohn's disease clinical trials. We are currently using these parameters as enrollment criteria in our ongoing long-term clinical study, known as PROTECT-1, which

will evaluate Traficet-EN's ability to induce response or remission, as well as at the drug's potential as maintenance therapy."

The oral presentation of Phase 2 data, titled "CCX282-B, an orally active inhibitor of chemokine receptor CCR9, shows anti-inflammatory and clinical activity in the treatment of Crohn's Disease" was provided today by Dr. Keshav as part of the Advances in Crohn's Disease session. Data from the Phase 2 trial were also selected for presentation during the "Best of UEGW" session sponsored by the American Gastroenterological Association (AGA) yesterday afternoon. The Phase 2 randomized double-blind, placebo-controlled clinical trial was designed to ev aluate Traficet-EN's safety and tolerability among patients with moderate-to-severe Crohn's disease. Traficet-EN was well-tolerated by patients participating in the Phase 2 study and the incidence of adverse events reported was generally similar in both the placebo and Traficet-EN groups.

ChemoCentryx is currently evaluating Traficet-EN in a large multi-national clinical trial. PROTECT-1 or the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Traficet-EN in patients with moderate-to-severe Crohn's disease. The study includes a 12-week Induction Period to evaluate the drug's ability to induce response/remission and a 36-week Maintenance Period to evaluate the drug's ability to maintain a treatment response.

About Traficet-EN

Traficet-EN, a small molecule, orally-available drug, is intended to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the activity of the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis -- the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in Crohn's disease. ChemoCentryx has completed four Phase I trials and one four-week Phase 2 trial of Traficet-EN demonstrating that the product candidate is well-tolerated and appropriate for once- or twice-daily oral dosing.

About Crohn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups or periods characterized by intense symptoms, in terspersed with periods of remission where symptoms decrease or disappear. As Crohn's disease is a chronic condition, patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few or no options beyond surgery.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a complex network of chemokine molecules, or ligands, and receptors that regulates inflammation. Based on their proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist, is currently in a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. ChemoCentryx is privately held. For more information, please refer to

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual resul ts, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the timing, success and cost of preclinical research and clinical studies, (ii) the timing, acceptability and review periods for regulatory filings, (iii) the availability of corporate partners, (iv) uncertainties relating to patent protection and intellectual property rights of third parties, (v) the impact of competitive products and technological changes, (vi) the availability of capital and the cost of capital, (vii) other vagaries in the biotechnology industry and (viii) other risks. ChemoCentryx undertakes no obligation to update or revise any forward-looking statements.

CONTACT: Media, Karen L. Bergman, +1-650-575-1509, or Michelle Corral,+1-415-794-8662, both of BCC Partners, for ChemoCentryx, Inc.; Investors,Susan M. Kanaya, Senior Vice President, Finance and Chief FinancialOfficer, or Markus J. Cappel, Ph.D. Chief Business Officer, both ofChemoCentryx, Inc., +1-650-210-2900,

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/13/2017)...   OrthoAtlanta has been named the official orthopedic ... (AFHC) for the 2018 College Football Playoff (CFP) National Championship ... Stadium in Atlanta, Georgia . OrthoAtlanta is ... campaign, participating in many activities leading up to, and including ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
Breaking Medicine News(10 mins):